Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 3/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 6/20 | 0.36 |
| ▸ | CCNK | O75909 | 4/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16041621 | 0.79 | PTGER4 (0.49) | PTGER4SCN5A | |
| SCHEMBL3997126 | 0.77 | AAK1 (0.46) | PTGER4KCNH3CHEK1 | |
| SCHEMBL16035266 | 0.77 | PTGER4 (0.41) | PTGER4KCNH3 | |
| SCHEMBL2578339 | 0.77 | PTGER4 (0.44) | PTGER4KCNH3 | |
| SCHEMBL19762006 | 0.77 | CDK9 (0.36) | PTGER4SCN5AKCNH3CDK9CCNK | |
| SCHEMBL26774940 | 0.75 | CDK9 (0.41) | PTGER4SCN5AKCNH3CDK9CCNK | |
| SCHEMBL29492736 | 0.75 | CDK9 (0.41) | PTGER4SCN5AKCNH3CDK9CCNK | |
| SCHEMBL15749040 | 0.75 | CHEK1 (0.40) | PTGER4SCN5AKCNH3CDK9CCNK | |
| SCHEMBL1565434 | 0.74 | KCNH3 (0.41) | PTGER4KCNH3CDK9CCNKCCNT1 | |
| SCHEMBL23759728 | 0.72 | POLB (0.44) | PTGER4KCNH3CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650358-B2 | Pyridine CDK9 kinase inhibitors | ABBVIE INC. (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2970200-A1 | PYRIDINE CDK9 KINASE INHIBITORS | Abbvie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014160017-A1 | PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275011-A1 | PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275011-A1 | PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK6 | PTGER4 1994/4885SCN5A 3455/4885KCNH3 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.